Hosch, René http://orcid.org/0000-0003-1760-2342
Weber, Manuel
Sraieb, Miriam
Flaschel, Nils
Haubold, Johannes
Kim, Moon-Sung
Umutlu, Lale
Kleesiek, Jens
Herrmann, Ken
Nensa, Felix
Rischpler, Christoph
Koitka, Sven
Seifert, Robert
Kersting, David
Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Received: 15 February 2022
Accepted: 30 June 2022
First Online: 29 July 2022
Declarations
:
: This study was conducted in compliance with the guidelines of the Institutional Review Board of the University Hospital Essen (approval number 20–9226-BO). The data were completely anonymized before being included in the study.
: Informed consent was obtained from participants included in the study.
: Informed consent was obtained from participants included in the study.
: Lale Umutlu is a Speaker/Advisory Board Member for Bayer Healthcare and Siemens Healthcare and received research grants from Siemens Healthcare outside of the submitted work. Ken Herrmann reports personal fees from Bayer SIRTEX Adacap Curium Endocyte IPSEN Siemens Healthineers GE Healthcare Amgen Novartis and ymabs personal fees and other from Sofie Biosciences non-financial support from ABX grants and personal fees from BTG outside the submitted work. Christoph Rischpler reports a research grant from Pfizer, consultancy for Adacap and Pfizer, speaker honoraria from Adacap, Alnylam, BTG, Curium, GE Healthcare, Pfizer, and Siemens Healthineers. David Kersting is supported by the Clinician Scientist Program of the Universitätsmedizin Essen Clinician Scientist Academy (UMEA)/German Research Foundation (DFG, Deutsche Forschungsgemeinschaft) and received research funding from Pfizer outside of the submitted work. Robert Seifert is supported by the Junior Clinician Scientist Program of the Universitätsmedizin Essen Clinician Scientist Academy (UMEA)/German Research Foundation (DFG, Deutsche Forschungsgemeinschaft). Manuel Weber reports fees from Boston Scientific, Terumo, Eli Lilly, and Advanced Accelerator Applications.